NEW YORK, June 30 - Cengent Therapeutics, formed by the merger in May of Structural Bioinformatics and GeneFormatics, said today that it has signed an agreement with AGY Therapeutics for its X-ray crystallography services.
Cengent's technology will be used to produce high-resolution structures of a human target protein and a proprietary inhibitor for AGY's lead optimization efforts in the area of central nervous system disease.
The agreement includes up-front and milestone payments, Cengent said. The company did not provide further financial details.